Cyteir Therapeutics, Inc.
NASDAQ:CYT
3.02 (USD) • At close March 15, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0.008 |
| Cost of Revenue
| 1.375 | 0.479 | 0.351 | 0.013 |
| Gross Profit
| -1.375 | -0.479 | -0.351 | -0.005 |
| Gross Profit Ratio
| 0 | 0 | 0 | -0.586 |
| Reseach & Development Expenses
| 34.624 | 30.959 | 16.765 | 12.768 |
| General & Administrative Expenses
| 13.546 | 11.3 | 4.178 | 3.345 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 |
| SG&A
| 13.546 | 11.3 | 4.178 | 3.345 |
| Other Expenses
| 2.109 | 0.133 | 0.12 | -0.008 |
| Operating Expenses
| 48.17 | 42.259 | 20.943 | 16.105 |
| Operating Income
| -48.17 | -42.259 | -20.943 | -16.105 |
| Operating Income Ratio
| 0 | 0 | 0 | -2,013.125 |
| Total Other Income Expenses Net
| 2.109 | 0.133 | 0.12 | 1.061 |
| Income Before Tax
| -46.061 | -42.126 | -20.823 | -15.044 |
| Income Before Tax Ratio
| 0 | 0 | 0 | -1,880.5 |
| Income Tax Expense
| -2.109 | -0.479 | 0 | 0 |
| Net Income
| -43.952 | -41.647 | -20.823 | -15.044 |
| Net Income Ratio
| 0 | 0 | 0 | -1,880.5 |
| EPS
| -1.25 | -2.14 | -0.87 | -0.77 |
| EPS Diluted
| -1.25 | -2.14 | -0.87 | -0.77 |
| EBITDA
| -47.502 | -41.78 | -20.592 | -15.89 |
| EBITDA Ratio
| 0 | 0 | 0 | -1,986.25 |